JMP Securities Reiterates Market Outperform on Sagimet Biosciences, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) and maintained a $48 price target.
June 07, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Sagimet Biosciences and maintained a $48 price target, indicating strong confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $48 by JMP Securities suggests strong confidence in Sagimet Biosciences' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100